Department of Health and Human Services$1.1M obligationsEnds Dec 18, 2021
Federal contract award
75N95020F00003
NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO). POP: 09/25/2020 TO 03/24/2021.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIDA |
| NAICS | 541712 |
| PSC | AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
| Parent award / vehicle | HHSN271201700016I |
| Set-aside | Not reported |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $751.4K |
| Current contract value | $751.4K |
| Potential contract value / ceiling | $751.4K |
| Start date | Sep 25, 2020 |
| Current end date | Dec 31, 2024 |
| Potential end date | Dec 31, 2024 |
| Latest award activity | Jul 14, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 9 of 9 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 14, 2026 | P00008 | $-1.0M | FY26 UDO INITIATIVE |
| Apr 11, 2024 | P00007 | $0 | NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO) |
| Sep 14, 2023 | P00006 | $1.4M | NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO) |
| Jan 26, 2023 | P00005 | $0 | NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO) |
| Feb 14, 2022 | P00004 | $10.1K | NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO). ADDITIONAL WORK FOR IN VITRO COMPATIBILITY/HEMOLYTIC POTENTIAL ASSAYS. |
| Jan 19, 2022 | P00003 | $0 | NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO) |
| Oct 29, 2021 | P00002 | $0 | NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO) |
| Mar 22, 2021 | P00001 | $0 | NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO). POP: 09/25/2020 TO 10/29/2021. MOD P00001 TO PROVIDE NO-COST EXTENSION AND UPDATE SECTION F CONTRACT CLAUSES. |
| Sep 24, 2020 | 0 | $323.8K | NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO). POP: 09/25/2020 TO 03/24/2021. |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.